论文部分内容阅读
红细胞生成素疗法对慢性肾功衰竭患者生活质量的影响秋译忠男等重组人红细胞生成素（ｒＨｕＥＰＯ）在日本已应用了３年。对１９９１年透析维持疗法中男性４６．６％、女性６１．９％使用此疗法进行调查表明，该剂已成为了透析期肾功衰竭者最常用治疗剂之一，并对透析前肾...
Effect of Erythropoietin Therapy on Quality of Life in Patients with Chronic Renal Failure Qiu-Zhong Zhong, et al. Recombinant human erythropoietin (rHuEPO) has been used in Japan for 3 years. A survey of 46.6% of men and 61.9% of women using dialysis maintenance therapy in 1991 showed that the agent has become one of the most commonly used therapeutic agents for dialysis renal failure, and has been used in dialysis of the anterior kidney. .